Johnson & Johnson (JNJ) Total Debt (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Total Debt came in at $55.0 billion in Q1 2026, up 5.23% year-on-year from $52.3 billion in Q1 2025, and up 14.72% quarter-over-quarter from $47.9 billion in Q4 2025.
Johnson & Johnson (JNJ) Total Debt (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Total Debt across 18 years of filings, most recently posting $55.0 billion for Q1 2026.
- Total Debt for Q1 2026 came in at $55.0 billion, up 5.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.0 billion (up 5.23% YoY), and the FY2025 annual result was $47.9 billion, up 30.84% from the prior year.
- Total Debt came in at $55.0 billion for Q1 2026 at Johnson & Johnson, up from $47.9 billion in the prior quarter.
- In the past five years, Total Debt ranged from a high of $55.0 billion in Q1 2026 to a low of $29.3 billion in Q4 2023.
- The 5-year median for Total Debt is $38.1 billion (2023), against an average of $40.5 billion.
- Across the five-year window, Total Debt surged 59.61% in 2023 and slumped 36.43% in 2024, its largest moves.
- Johnson & Johnson's Total Debt stood at $32.0 billion in 2022, then slipped by 8.41% to $29.3 billion in 2023, then rose by 24.89% to $36.6 billion in 2024, then soared by 30.84% to $47.9 billion in 2025, then increased by 14.72% to $55.0 billion in 2026.
- The last three Total Debt figures came in at $55.0 billion (Q1 2026), $47.9 billion (Q4 2025), and $45.8 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -18.89 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 43.37 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 54.99 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 64.53 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 49.12 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 57.32 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 22.17 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 64.46 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 44.46 Bn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 54.99 Bn |
| Dec 28, 2025 | 47.93 Bn |
| Sep 28, 2025 | 45.80 Bn |
| Jun 29, 2025 | 50.76 Bn |
| Mar 30, 2025 | 52.25 Bn |
| Dec 29, 2024 | 36.63 Bn |
| Sep 29, 2024 | 35.75 Bn |
| Jun 30, 2024 | 41.49 Bn |
| Mar 31, 2024 | 33.63 Bn |
| Dec 31, 2023 | 29.33 Bn |
| Oct 1, 2023 | 29.92 Bn |
| Jul 2, 2023 | 45.60 Bn |
| Apr 2, 2023 | 52.91 Bn |
| Jan 1, 2023 | 39.64 Bn |
| Oct 2, 2022 | 32.03 Bn |
| Jul 3, 2022 | 32.60 Bn |
| Apr 3, 2022 | 33.15 Bn |
| Jan 2, 2022 | 33.75 Bn |
| Oct 3, 2021 | 33.93 Bn |
| Jul 4, 2021 | 33.48 Bn |